RT Journal Article
SR Electronic
T1 Plasma proteomic evidence for increased Alzheimer’s disease-related brain pathology after SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.02.24302132
DO 10.1101/2024.02.02.24302132
A1 Duff, Eugene P
A1 Zetterberg, Henrik
A1 Heslegrave, Amanda
A1 Dehghan, Abbas
A1 Elliot, Paul
A1 Allen, Naomi
A1 Runz, Heiko
A1 Laban, Rhiannon
A1 Veleva, Elena
A1 Whelan, Christopher D
A1 Sun, Benjamin B
A1 Matthews, Paul M
YR 2024
UL http://medrxiv.org/content/early/2024/06/24/2024.02.02.24302132.abstract
AB Prior studies have suggested that systemic viral infections may increase risks of dementia. Whether this holds true for SARS-CoV-2 virus infections remains uncertain but is of great consequence for predicting future dementia rates. We examined this by comparing changes in plasma biomarkers in UK Biobank participants before and after serology confirmed SARS-CoV-2 infections. We discovered biomarker changes associated with increased AD risk within this population. SARS-CoV-2 infection was associated with reduced plasma Aβ42:Aβ40 concentration ratios, and in more vulnerable participants, lower plasma Aβ42 and higher plasma pTau-181. These biomarker changes, which have been associated with brain beta-amyloid accumulation in prodromal AD, were associated here with increased brain imaging signatures of AD, poorer cognitive scores, and worse assessments of overall health. Changes were greater in participants who had been hospitalised with COVID-19 or had previously reported hypertension. Our data provide evidence for the hypothesis that SARS-CoV-2 can be associated with accelerating brain pathology related to prodromal AD.Competing Interest StatementHZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). PMM is a consultant for Biogen, Sudo Therapeutics, Nimbus, Astex, GSK and Sangamo. He received research funding for aspects of this work from Biogen and the UK DRI. He has research funding unrelated to this work from Biogen and Bristol Meyers Squibb.Funding Statement EPD is supported jointly by funding to PMM from the UK Dementia Research Institute and from the NIHR Imperial Biomedical Research Centre, in which he is a member of the Multiple Long-Term Conditions theme. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme - Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). PMM acknowledges generous personal support from the Edmond J Safra Foundation and Lily Safra and an NIHR Senior Investigator Award. His work additionally is supported by the UK Dementia Research Institute, which receives its funding from UK DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK and, for this research specifically, Biogen.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank is approved by the North West Multi-Centre Research Ethics Committee (MREC) to obtain and share data and samples from volunteer participants. Written informed consent was obtained from all participants (http://www.ukbiobank.ac.uk/ethics/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data is available upon application from the UK Biobank. https://www.ukbiobank.ac.uk/